ReviewMolecular psychiatry2025
The mesocorticolimbic system in stimulant use disorder.
Review in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Beyond total BDNF: The proBDNF/mBDNF balance in substance use disorders.Neurobiology of disease · 2026Review
- Mesocorticolimbic Dopamine-Reward Tract Alterations and the 'Dark Side' of Methamphetamine Addiction.Addiction biology · 2026Article
- Automated Facial Emotion Recognition System Detects Altered Emotional Processing During Craving Induction in Individuals with Substance Use Disorder.Healthcare (Basel, Switzerland) · 2026Article
- Reimagining the biopsychosocial model: hierarchical mechanisms from transdiagnostic to precision psychiatry.Journal of psychiatry & neuroscience : JPN · 2026Review
- GPR4 regulates temporally dynamic and sex-dependent cocaine-induced locomotor sensitization.Frontiers in molecular neuroscience · 2026Article
- Lost in translation: why don't dopamine D2 antagonists cure addictions?Journal of psychiatry & neuroscience : JPN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Stimulant Use Disorder (StUD) is a pervasive and extremely dangerous form of addiction for which there are currently no approved medications. Discovering treatments will require a deep understanding of the neural mechanisms underlying the behavioral effects of stimulant drugs. A major target is the mesocorticolimbic system. Individual differences in mesocorticolimbic function can influence the propensity to initiate stimulant use and the risk for stimulant use disorders. Since repeated stimulant use can further alter mesocorticolimbic function, these pathways may serve as a target for both early interventions aimed at preventing the onset of harmful stimulant use and treatments designed to alleviate addiction symptoms. Here we review evidence from studies in both humans and laboratory animals, focusing on the neurotransmitter systems most strongly implicated in StUD, primarily dopamine and, to a lesser extent, glutamate. We identify evidence of (i) complex, non-linear perturbations to mesocorticolimbic function related to stimulant use, and (ii) gaps in knowledge and opportunities for research to improve our understanding of the determinants and consequences of StUD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.